多巴丝肼、普拉克索联合治疗帕金森病的效果及对PARK2、CKMT1A、Netrin-1的影响  

AEfficacy of Combination of Dopa Serazid and Pramexol in the Treatment of Parkinson's Disease and Its Effect on PARK2,CKMT1A and Netrin-1

作　　者：嵇继宇 王莉 田小军[1] 王玉梅[1] 苏洲[1] Ji Jiyu;Wang Li;Tian Xiaojun;Wang Yumei;Su Zhou(Ward 1,Department of Neurology,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,China)

机构地区：[1]新乡医学院第一附属医院神经内科一病区,新乡453100

出　　处：《成都医学院学报》2024年第1期66-69,74,共5页Journal of Chengdu Medical College

基　　金：2019年度河南省医学科技攻关计划联合共建项目(No:LHGJ20191475)。

摘　　要：目的探究多巴丝肼、普拉克索联合治疗帕金森病(PD)的效果及对人帕金森病蛋白2(PARK2)、线粒体肌酸激酶1A(CKMT1A)及神经轴突导向因子1(Netrin-1)的影响。方法选择2021年7月至2023年6月于新乡医学院第一附属医院治疗的PD患者108例为研究对象,依据随机数字表法分为试验组和对照组,每组54例。对照组行多巴丝肼治疗,试验组行多巴丝肼、普拉克索联合治疗。观察两组治疗前后PD严重程度,认知功能水平,睡眠障碍情况,血清PARK2、CKMT1A、Netrin-1水平和不良反应。结果治疗后,试验组统一PD评定量表(UPDRS)各分项得分及总分、匹兹堡睡眠质量指数量表(PSQI)评分均低于对照组(P<0.05),简易智力状态检查量表(MMSE)评分高于对照组(P<0.05)。试验组血清PARK2、Netrin-1水平均高于对照组(P<0.05),血清CKMT1A水平低于对照组(P<0.05)。试验组总有效率大于对照组(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论多巴丝肼、普拉克索联合治疗PD可缓解患者症状,提高其认知功能及睡眠质量,改善血清PARK2、CKMT1A、Netrin-1水平。Objective To study the efficacy of dopa serazid combined with pramexol in the treatment of Parkinson's disease(PD)and its effect on human Parkinson's disease protein 2(PARK2),creatine kinase mitochondrial 1A(CKMT1A)and neuron axon guidance factor-1(Netrin-1).Methods A total of 108 PD patients treated in the First Affiliated Hospital of Xinxiang Medical University from July 2021 to June 2023 were selected as the the research objects.They were divided into either an experimental group(n=54)or a control group(n=54)according to random number table method.The control group was treated with dopa serizid,while the experimental group was treated with combination therapy of dopa serizid and pramexol.The severity of PD,cognitive function,sleep disorders,serum levels of PARK2,CKMT1A,and Netrin-1,and adverse reactions before and after treatment were observed.Results After treatment,the scores of all sub items and the total score of the Unified Parkinson's Rating Scale(UPDRS),and the score of Pittsburgh Sleep Quality Index(PSQI)in the experimental group were lower than those in the control group(P<0.05),while the score of the Mini Mental State Examination Scale(MMSE)in the experimental group were higher than that in the control group(P<0.05).After treatment,the serum levels of PARK2 and Netrin-1 in the experimental group were higher than those in the control group(P<0.05),while the serum level of CKMT1A in the experimental group was lower than that in the control group(P<0.05).The total effective rate in the experimental group was higher than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of dopa serazid and pramexol can alleviate the symptoms of PD patients,improve their cognitive function,sleep quality,and their levels of serum PARK2,CKMT1A and Netrin-1.

关 键 词：多巴丝肼 普拉克索 帕金森病 人帕金森病蛋白2 线粒体肌酸激酶 神经轴突导向因子1 

分 类 号：R742.5[医药卫生—神经病学与精神病学]